Press Release: PreventionGenetics : PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis

MARSHFIELD, Wis.--(BUSINESS WIRE)--PreventionGenetics, a wholly owned subsidiary of Exact Sciences Corp., announced that it is the new administrator of Alnylam Act,® a sponsored genetic testing program by Alnylam Pharmaceuticals, Inc. The program, called Alnylam Act®, provides genetic testing for the diagnosis of acute hepatic porphyria, primary hyperoxaluria type 1 (PH1), and hereditary ATTR (hATTR) amyloidosis. Along with genetic testing, the program includes access to pre and post-test genet